Close Menu
Tamar BridgeTamar Bridge
  • Home
  • Latest News
  • About Us
    • Our Team
    • Join the team
  • Policies
    • Cookies
    • Terms & Conditions
    • Privacy Policy
  • Sitemap
  • —————–
  • Money
  • Tech
  • Lifestyle
  • News
  • Health
  • Property
  • Business
  • Travel
  • Motors
  • Contact Us
Facebook X (Twitter) LinkedIn
Facebook X (Twitter)
Tamar BridgeTamar Bridge
Contact
  • About Us
    • Our Team
    • Contact Us
    • Join the team
  • News
  • Culture
  • Money
  • Business
  • Health
  • Lifestyle
  • Tech
  • Motors
Tamar BridgeTamar Bridge
Home»News»Court of Appeal Upholds CMA’s Cartel Finding in Pharmaceutical Price Fixing Case
four people inside mart
News

Court of Appeal Upholds CMA’s Cartel Finding in Pharmaceutical Price Fixing Case

Sam AllcockBy Sam Allcock06/09/20243 Mins Read

The Court of Appeal (CoA) has upheld the Competition and Markets Authority’s (CMA) finding of cartel infringement in a significant ruling that addresses an illegal market-sharing agreement in the supply of a crucial medicine. The decision overturns a previous ruling by the Competition Appeal Tribunal (CAT) that had set aside the CMA’s original finding on procedural grounds.

In July 2021, the CMA concluded that pharmaceutical companies Auden Mckenzie and Actavis UK had engaged in anti-competitive practices by charging excessive prices for hydrocortisone tablets and paying a competitor, AMCo (now Advanz), to remain out of the market. This practice led to a dramatic increase in NHS expenditure on the drug, soaring from approximately £500,000 annually to over £80 million. The CMA imposed over £260 million in penalties to address the seriousness of these practices and their impact on the NHS.

The CAT initially upheld the CMA’s findings in September 2023 but later ruled in March 2024 that the CMA had not adequately cross-examined John Beighton, the former CEO of Advanz, on the market-sharing agreement. The tribunal’s subsequent judgment found procedural flaws in the CMA’s handling of the case, prompting an appeal by the CMA.

Today, the Court of Appeal overturned the CAT’s ruling, affirming the CMA’s original findings and its handling of the case. The CoA deemed the CMA’s cross-examination of Beighton as appropriate and upheld the CMA’s penalties. The court criticised the CAT for making new findings and conducting an additional examination that led to the reversal of the original decision, calling the approach “inappropriate” and “unjust.”

Sarah Cardell, Chief Executive of the CMA, welcomed the ruling, stating, “The CMA’s imposition of significant penalties was intended to rectify the market-sharing agreement that deprived the NHS of potential savings through competitive pricing. We are pleased that the Court of Appeal recognised the clarity and fairness of our case.”

The case involved several pharmaceutical firms, including Auden Mckenzie, which later became Actavis UK (now Accord-UK), and AMCo (Advanz Pharma). The CMA’s investigation revealed that Auden/Actavis UK, in a bid to protect its monopoly, made substantial payments to competitors to prevent their market entry with hydrocortisone tablets between 2008 and 2018. Despite the CAT’s earlier judgment confirming the excessive pricing and market-sharing agreement, the tribunal had expressed concerns over procedural fairness, leading to its initial reversal of the CMA’s decision.

The CoA’s ruling also reinstates the CAT’s earlier findings that the CMA’s decision on the existence and nature of the 10mg hydrocortisone agreement was correct. However, the tribunal’s additional findings on dishonesty and other matters have been overturned.

This case underscores the importance of rigorous competition enforcement and adherence to proper procedures in ensuring fair market practices. The ruling marks a significant step in maintaining regulatory oversight and protecting public interests in the pharmaceutical sector.

appeal cartel case cma’s court finding fixing news pharmaceutical price upholds
Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
Previous ArticleHisense Showcases Groundbreaking Home Entertainment Tech at IFA 2024
Next Article Marks & Spencer | Clothing, Home, Food & Gifts | M&S

Other stories that may interest you

TrendsFinGroup.com review – Is Trends Financial Group a trusted platform for Canadian traders?

08/05/2025

Phoenix Ikner Parents, The Tragic Family Story Behind a Shattered Future

29/04/2025

FEXSE Opens Digital Doors to Art, Real Estate and Luxury Asset Investment

14/04/2025

Latest Stories

TrendsFinGroup.com review – Is Trends Financial Group a trusted platform for Canadian traders?

08/05/2025

Paulo Avelino’s Girlfriend, The Untold Story Behind His Relationship with Kim Chiu

06/05/2025

Tim Duncan’s Girlfriend Vanessa Macias, The Hidden Gem Behind The NBA Legend’s Quiet Life

06/05/2025

Amanda Kloots’ New Romance, Who is Her Boyfriend, Justin Gimelstob? The Unlikely Couple’s Red Carpet Debut

06/05/2025
  • Facebook
  • Twitter
  • LinkedIn
Sections
  • News
  • Culture
  • Money
  • Business
  • Health
  • Lifestyle
  • Tech
  • Motors

Tamar Bridge News is your trusted guide through the currents of UK news, committed to bridging the gap between information and insight with clarity, precision, and a human-centric approach.

Company

  • Home
  • Latest News
  • About Us
  • Our Team
  • Contact Us
  • Join the team
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Sitemap

Latest Stories

TrendsFinGroup.com review – Is Trends Financial Group a trusted platform for Canadian traders?

By Sam Allcock

Paulo Avelino’s Girlfriend, The Untold Story Behind His Relationship with Kim Chiu

By Sam Allcock

Tim Duncan’s Girlfriend Vanessa Macias, The Hidden Gem Behind The NBA Legend’s Quiet Life

By Sam Allcock
© 2025 Tamar Bridge News | All rights reserved

Type above and press Enter to search. Press Esc to cancel.